Biogen partners with Stoke Therapeutics on drug for severe epilepsy Stoke’s therapy may become first treatment to target underlying, genetic cause of Dravet syndrome

https://www.statnews.com/2025/02/18/biogen-stoke-therapeutics-dravet-syndrome-zorevunersen/